- Conditions
- Breast Cancer, Invasive Breast Cancer
- Interventions
- Pre-neoadjuvant radiotherapy (NART) biopsy, Neoadjuvant radiotherapy, Unilateral total mastectomy with axillary lymph node dissection
- Diagnostic Test · Radiation · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1585–1608
of 1,617
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer
- Interventions
- Neoadjuvant Chemotherapy, Radiation Therapy, MRI, Breast Cancer Surgery, Biopsy, Biospecimen collection
- Drug · Radiation · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Stroke
- Interventions
- Blood draw, Stroke blood draw
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Breast Cancer
- Interventions
- Predictive Model, Breast Imagers
- Diagnostic Test
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, BRCA-Associated Malignant Neoplasm, BRCA Hereditary Ovarian Carcinoma, Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Primary Peritoneal Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Breast Carcinoma, Unresectable Fallopian Tube Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Ovarian Carcinoma, Unresectable Pancreatic Carcinoma, Unresectable Primary Peritoneal Carcinoma
- Interventions
- Dostarlimab, Niraparib, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Biological · Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Posttraumatic Stress Disorder, Tinnitus
- Interventions
- resting-state functional MRI, Clinician Administered PTSD Scale for the DSM-5 (CAPS-5), Tympanometry, Tinnitus Assessment, Otoscopy, Pure tone air and bone-conduction, Speech testing, Loudness Discomfort, Quick Speech in Noise Test, Distortion-Product Otoacoustic Emissions (DPOAE)
- Diagnostic Test
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- HIV Infection
- Interventions
- Adaptive WM CogMed Training, Nonadaptive WM CogMed Training
- Other
- Lead sponsor
- University of Hawaii
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Magrolimab, Olaparib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Costa Mesa, California • Orange, California • The Bronx, New York + 1 more
- Conditions
- Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Tazemetostat
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Derby, Connecticut + 28 more
- Conditions
- Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
- Interventions
- Biospecimen Collection, Carboplatin, Computed Tomography, Fluorothymidine F-18, Positron Emission Tomography, Veliparib
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 3
- States / cities
- The Bronx, New York • Columbus, Ohio
- Conditions
- Adrenocortical Adenoma, Endometrial Stromal Sarcomas
- Interventions
- MRI, CT or ultrasound was permitted if MRI was contraindicated, Dexamethasone Supression Test, Sonogram, Biopsy, BGG492
- Procedure · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 4
- States / cities
- Tallahassee, Florida • Baltimore, Maryland • Hoffman, New Jersey + 1 more
- Conditions
- Lumbar Disc Disease
- Interventions
- NOCISCAN-LS Disc MR Spectroscopy
- Other
- Lead sponsor
- Nocimed, LLC
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Plano, Texas
- Conditions
- Oropharyngeal Squamous Cell Carcinoma (SCC)
- Interventions
- PRGN-2009, Pembrolizumab, EKG, CT, PET scan, MRI, Biopsy
- Biological · Drug · Diagnostic Test + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Electrocardiogram, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Rituximab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Hackensack, New Jersey
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Sarcomatoid Urothelial Carcinoma, Kidney Medullary Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Penile Carcinoma, Penile Squamous Cell Carcinoma, Renal Cell Carcinoma, Renal Pelvis Urothelial Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 8
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 3 more
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- saracatinib, pharmacogenomic studies, pharmacological study, positron emission tomography, fludeoxyglucose F 18, laboratory biomarker analysis
- Drug · Other · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 4 more
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 1,377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
- Conditions
- Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Etentamig, Positron Emission Tomography, Questionnaire Administration
- Procedure · Biological · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Myc Inhibitor OMO-103
- Procedure · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Prostate Cancer
- Interventions
- Bi-parametric MRI-based cascaded deep-learning AI algorithm
- Device
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Brain Injuries, Traumatic
- Interventions
- Goal-Oriented Attentional Self-Regulation (GOALS), Brain Health Education (BHE), fMRI
- Behavioral · Other · Device
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 2
- States / cities
- San Francisco, California
- Conditions
- Inflammatory Bowel Disease, Crohn Disease
- Interventions
- Coronal T1 weighted spin echo images, Spin-lattice relaxation (T1), Magnetic resonance spectroscopy, Blood Draw
- Diagnostic Test
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 13 Years to 20 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Endometriosis, Endometrioma
- Interventions
- Radiotracer Injection, Imaging, Rectal Ultrasound Gel Injection
- Drug · Diagnostic Test · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 60 participants
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
- Interventions
- Axatilimab, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Retifanlimab
- Biological · Procedure · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Portland, Oregon